Having trouble accessing articles? Reset your cache.

Rescula unoprostone isopropyl: Phase III started

R-Tech began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 0.15% UF-021 for 52 weeks in about 180 patients. The trial

Read the full 220 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE